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Background: Elevated plasma B-type natriuretic peptide (BNP) is a predictor of outcome and helpful for
risk stratiﬁcation in aortic stenosis (AS). However, left ventricular (LV) diastolic dysfunction progresses
with aging and may also inﬂuence plasma BNP levels in elderly patients. We hypothesized that plasma
BNP levels may be inﬂuenced by age in severe AS, and that factors that affect the elevation of plasma BNP
levels may be different between elderly and younger patients with AS.
Methods: We performed echocardiography in 341 patients with severe AS [aortic valve area
(AVA) <1.0 cm2] and classiﬁed them into two groups by age (elderly ≥75 years old, n=201; younger
patients <75 years old, n=140). We used multivariate linear regression analysis to assess the factors that
determine plasma BNP levels in both groups.
Results: Age was found to be one of the independent determinants of plasma BNP levels in all
patients (ˇ =0.135, p=0.005). Although AVA was similar in the two groups, plasma BNP levels and
E/e′ were signiﬁcantly higher in elderly than younger patients [133.0 (IQR, 73.3–329.7) pg/dl vs 92.8
(IQR, 40.6–171.8) pg/dl, p<0.01; 20±8 vs 16±6, p<0.01, respectively). In multivariate stepwise linear
regression analysis, AVA index, LV ejection fraction,mass index, E/e′, estimated systolic pulmonary artery
pressure (eSPAS), and the presence of atrial ﬁbrillation were independent determinants of plasma BNP
levels in younger patients. In contrast, the independent determinants of plasma BNP levels in elderly
′patients were LV ejection fraction, mass index, E/e , eSPAS, the presence of atrial ﬁbrillation, age, and
hemoglobin levels, but not AVA index.
Conclusions: There may be differences in the factors that inﬂuence plasma BNP levels between elderly
and younger patients with severe AS. In elderly patients, plasma BNP levels may be inﬂuenced more by
these factors than AS severity compared with younger patients.
4 Jap© 201
ntroductionWith the aging of society, the number of patients with aortic
tenosis (AS) is increasing, and AS has become a common valvular
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disease [1]. Surgical intervention is critical to improve prognosis
in patients with AS, and the importance of risk stratiﬁcation and
deciding optimal timing for surgery has been emphasized.
Previous reports have shown that the B-type natriuretic peptide
(BNP) level is a predictor of outcome and is helpful for risk strat-
iﬁcation of AS [2–4], and BNP might be useful in determining the
optimal timingofnon-pharmacological interventions suchas aortic
valve replacement (AVR) in patients with severe AS without symp-
toms or cardiac dysfunction. BNP is predominantly released from
the left ventricular (LV) myocardium in response to elevated LV
served.
Cardi
e
p
t
c
a
L
i
a
a
a
p
f
W
e
a
a
p
M
S
A
d
a
W
a
u
c
r
c
b
o
s
a
c
p
Y
f
B
r
P
s
t
−
s
S
s
t
E
a
c
D
c
p
w
T
s
TS. Sasaki et al. / Journal of
nd-systole wall stress and hypertrophy, which may gradually
rogress in AS and lead to LV systolic and diastolic dysfunc-
ions [5–8]. In the modern era, the prevalence of a degenerative
alciﬁed valve has increased with aging and the prevalence of
therosclerosis is the most common etiology of AS [1]. However,
V diastolic dysfunction also progresses with aging [9,10] and may
nﬂuence plasma BNP levels in elderly patients with AS [11]. In
ddition, plasmaBNP level ismultifactorial and could increasewith
ging even in a healthy population [11]. We hypothesized that
ge-related physical changes may inﬂuence plasma BNP levels in
atients with severe AS and plasma BNP levels may not be use-
ul for assessing LV dysfunction caused by AS in elderly patients.
e aimed to investigate (1) whether plasma BNP levels are inﬂu-
nced by age in patientswith severe AS, and if so, (2)whether there
re differences in the clinical and echocardiographic factors associ-
tedwith elevated plasma BNP levels between elderly and younger
atients with severe AS.
ethods
ubjects
In this study, we enrolled 341 patients with isolated severe
S [aortic valve area (AVA) <1.0 cm2] referred to our echocar-
iographic laboratories. They were divided into two groups by
ge, with patients ≥75 years old included in the elderly group.
e compared the clinical and echocardiographic factors associ-
ted with elevated plasma BNP levels between the two groups
sing multivariate stepwise linear regression analysis. Exclusion
riteria were pulmonary disease, more than mild aortic or mitral
egurgitation or mitral stenosis, and renal insufﬁciency (creatinine
learance <30ml/min). Ethical approval for this study was granted
y the Sakakibara Heart Institute and Juntendo University School
f Medicine ethics committees, and patients gave informed con-
ent prior to participation in the study. We collected clinical data
nd information on symptoms in the study patients from medi-
al records that were reviewed by experienced cardiologists. The
resence of symptoms was deﬁned as exertional dyspnea (New
orkHeart Association ≥2), angina, presyncope, syncope, and heart
ailure. First, we explored the independent determinant of plasma
NP levels in all study patients using multivariate stepwise linear
egression analysis.
lasma BNP measurements
Plasma BNP levels were determined at the time of diagnosis of
evere AS. Venous blood (4ml) was obtained from each patient and
ransferred to tubes containing aprotinin and EDTA, and stored at
20 ◦C until analysis. The plasma concentration of BNP was mea-
ured using a chemiluminescent enzyme immunoassay kit (MI02
hionogi BNP; Shionogi Co. Ltd., Osaka, Japan) and an immunoassay
ystem(MI02;A&TCo. Ltd., Yokohama, Japan). Theminimumquan-
ity of human BNP that is detectable using this system is 4pg/ml.
chocardiographic study
Doppler echocardiography was performed using commercially
vailable echocardiographic machines. All patients underwent a
omprehensive examination that included two-dimensional and
oppler echocardiography by an experienced sonographer or
ardiologist. The peak aortic valve (AV) velocity and mean AV
ressure gradient were derived from transaortic ﬂow recorded
ith continuous-wave Doppler using a multi-window approach.
he AVA was calculated using the continuity equation [12]. The
everity of AS was assessed by the AVA index in this study.
he LV end-diastolic volume (EDV) and end-systolic volumeology 64 (2014) 476–481 477
(ESV) were measured by the method of disks using 2D images
obtained from both the apical four- and two-chamber views. The
LV ejection fraction was calculated by the following equation:
100× (EDV−ESV)/EDV [13]. The LV mass was calculated using
diastolic measurements of LV internal diameter and wall thickness
on 2D echocardiography according to the formula recommended
by the American Society of Echocardiography (ASE): LV mass
(g) = 0.8× {1.04[(IVST+ LVID+PWT)3 − (LVID)3]}+6g (IVST, inter-
ventricular septal wall thickness; LVID, LV internal diameter; PWT,
posteriorwall thickness) [13]. Then, left ventricularmass indexwas
calculated as LV mass/body surface area.
For assessing diastolic function, pulsed-wave Doppler examina-
tion of mitral inﬂow and tissue Doppler imaging of mitral annular
motion at the septumwere alsoperformed, according to a guideline
fromASE [14]. Peak velocities of early (E), late (A) diastolic ﬂow and
E/A ratio were measured by pulsed-wave Doppler examination of
mitral inﬂow. Early (e′) diastolic annular velocities were measured
from tissue Doppler imaging. The ratio of mitral E to e′ (E/e′) was
also calculated as an index of LV ﬁlling pressure.
Estimated systolic pulmonary artery pressure (eSPAP) was cal-
culated using the peak pressure gradient of tricuspid regurgitation
and right atrial pressure that was estimated on the basis of infe-
rior vena cava size and collapse [15]. Furthermore, according to
previous reports [14,16], we classiﬁed the diastolic function in all
subjects into one of the four categories [grade 0 (normal), grade 1,
grade 2, or grade 3].
Statistical analysis
Continuous data are expressed as mean± SD or median [inter-
quartile range (IQR)], as appropriate. Categorical data are presented
as the number (percentage) of patients. Continuous variables
were compared using Student’s t-test or Mann–Whitney U-test,
as appropriate. Categorical variables were compared using Fisher’s
exact test or a chi-square test, whenever appropriate. Pearson’s lin-
ear correlation analysis was used to determine the correlations
between log10 BNP and the echocardiographic and clinical vari-
ables. Multivariate linear regression analysis was also performed
to determine the independent determinants of log10 BNP. Vari-
ables with p<0.05 in univariate analysis were incorporated into
the linear regressionmodel. Comparing independent determinants
of log10 BNP between two groups, all variables with p<0.05 in
univariate analysis either in the younger or elderly group were
incorporated into the linear regression model. AVA index was used
as a variable in the linear regressionmodel for assessingAS severity,
because high prevalence of severe AS with low ﬂow and low-
pressure gradient despite normal LV ejection fraction has been
reported [17]. Pairs with missing values were excluded from the
analysis. SPSS version 17.0 (SPSS Inc., Chicago, IL, USA)was used for
statistical analyses. Statistical signiﬁcance was deﬁned as p<0.05.
Results
The median of plasma BNP levels was 115.7pg/dl (IQR,
55.7–247.5pg/dl). A logarithmic transformation of plasma BNP
was performed for assessing correlations with variables because
plasma BNP levels did not follow a normal distribution. All clini-
cal characteristics and echocardiographic parameters that showed
signiﬁcant correlationswithplasmaBNP levels inunivariate regres-
sion analysis in a whole population are shown in Table 1. Other
clinical characteristics including gender (r=0.057, p=0.297) did
not have signiﬁcant correlations with plasma BNP levels. When
we explored the determinant factors of plasma BNP levels, age
was found to be one of the independent determinants of plasma
BNP levels in a whole population with severe AS (Table 1). The
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Table 1
Factors associatedwith log B-type natriuretic peptide in univariate andmultivariate
linear regression analyses.
Variable All patients
Univariate Multivariate
r p-Value B p-Value
Age 0.328 <0.001 0.135 0.005
Atrial ﬁbrillation <0.208 <0.001 0.157 <0.001
Beta blocker use <0.158 0.004 0.163 <0.001
Hemoglobin −0.229 <0.001 −0.130 0.006
Creatinine clearance <−0.184 0.001 – –
EDV index 0.228 <0.001 – –
ESV index 0.367 <0.001 – –
Ejection fraction <−0.396 <0.001 −0.208 <0.001
LV mass index <0.462 <0.001 0.251 <0.001
AVA index −0.342 <0.001 −0.161 <0.001
E/A (n=312) 0.198 <0.001 – –
E/e′ 0.438 <0.001 0.206 <0.001
eSPAP (n=316) 0.298 <0.001 0.130 0.006
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Table 3
Echocardiographic data.
Variable <75 years (N=140) ≥75 years (N=201) p-Value
AS severity
AVA index (cm2/m2) 0.46±0.12 0.46±0.13 0.60
Peak AV velocity (m/s) 4.8±1.0 4.8±0.9 0.38
Mean AV PG (mmHg) 55±22 53±22 0.44
Left atrial diameter (cm) 4.0±0.7 4.0±0.6 0.84
Left ventricle
EDV index (ml/m2) 58±22 54±23 0.06
ESV index (ml/m2) 21±13 21±15 0.79
Ejection fraction (%) 65±9 63±10 0.16
Mass index (g/m2) 132±35 129±35 0.37
E/A (n=312) 0.8±0.4 0.8±0.3 0.06
E/e′ 16±6 20±8 <0.01
e′ 4.8±1.4 4.1±1.3 <0.01
Diastolic dysfunction class
Grade 0 1 (1%) 0 (0%) 0.86
Grade 1 67 (48%) 115 (57%) 0.11
Grade 2 59 (42%) 63 (31%) 0.05
Grade 3 3 (2%) 4 (2%) 0.92
eSPAP, mmHg (n=316) 31±7 32±8 0.48
AS, aortic stenosis; AVA, aortic valve area; PG, pressure gradient; EDV, end-diastolic
volume; ESV, end-systolic volume index; E, peak velocity of early diastolic ﬂow ofDV, end-diastolic volume; ESV, end-systolic volume index; AVA, aortic valve area;
, peak velocity of early diastolic ﬂow of mitral inﬂow; A, peak velocity of late
iastolic ﬂowofmitral inﬂow; eSPAP, estimated systolic pulmonary artery pressure.
linical and echocardiographic characteristics of patients in each
ge group are presented in Tables 2 and 3. Body mass index, body
urface area, hemoglobin, and creatinine clearance were signiﬁ-
antly smaller in elderly patients, whereas the plasma BNP levels
nd the prevalence of coronary artery disease were signiﬁcantly
igher in elderly patients. Both elderly and younger patients had
imilar AVA index, peak AV velocity, and mean AV pressure gra-
ient, despite higher plasma BNP levels in elderly patients. Elderly
atients had decreased e′ and increased E/e′ (p<0.01 for both) com-
ared with younger patients, probably because of age-related LV
iastolic dysfunction.
Table 4 shows the comparison of factors that had signiﬁ-
ant correlations with log10 BNP among the demographic, clinical,
nd echocardiographic variables between the two groups. Other
ariables that are not listed in Table 4 did not have signiﬁcant
orrelations with log10 BNP. Although log10 BNP and AVA index
ere correlated in both younger and elderly patients (Fig. 1), the
able 2
atient clinical characteristics.
Variable <75 years
(N=140)
≥75 years
(N=201)
p-Value
Male 64 (46%) 81 (40%) 0.42
Age (years) 67±7 81±4 <0.01
Body mass index (kg/m2) 23.8±3.8 22.9±3.3 0.02
Body surface area (m2) 1.6±0.2 1.5±0.2 <0.01
Symptomatic 91 (65%) 135 (67%) 0.76
Comorbidity
Hypertension 84 (60%) 137 (68%) 0.14
Diabetes mellitus 32 (23%) 45 (22%) 0.91
Hyperlipidemia 72 (51%) 99 (49%) 0.78
Coronary artery disease 36 (26%) 75 (37%) 0.03
Cerebrovascular disease 10 (7%) 20 (10%) 0.48
Atrial ﬁbrillation 10 (7%) 19 (10%) 0.58
Medications
RAS-I 70 (50%) 108 (54%) 0.57
Beta blocker 43 (31%) 45 (22%) 0.11
Calcium channel blocker 54 (39%) 87 (43%) 0.45
Statin 65 (46%) 93 (46%) 0.98
Laboratory data
Hemoglobin (g/dl) 13.4±1.4 12.2±1.6 <0.01
Creatinine clearance (ml/min) 70±15 61±17 <0.01
BNP (pg/dl) 92.8 (IQR;
40.6–171.8)
133.0 (IQR;
73.3–329.7)
<0.01
AS-I, renin–angiotensin system inhibitor; BNP, B-type natriuretic peptide. Data
xcept BNP are expressed as the mean± SD the number (percentage) of patients.
NP is expressed as the median (IQR).mitral inﬂow;A, peak velocity of late diastolic ﬂowofmitral inﬂow; e′ , early diastolic
annular velocity; eSPAP, estimated systolic pulmonary artery pressure.
association between plasma BNP levels and other variableswas not
the same in the two patient groups (Table 4). In multivariate step-
wise linear regression analysis, AVA index, atrial ﬁbrillation, beta
blocker use, LV ejection fraction, LV mass index, E/e′, and eSPAP
were found to be independent determinants of plasma BNP levels
in younger patients. On the other hand, the severity of AS, as mea-
sured by the AVA index, was not an independent determinant of
plasma BNP levels in elderly patients. In elderly patients, age and
hemoglobin levels were also independent determinants of plasma
BNP levels. Other factors including age were assumed to contribute
to elevated plasma BNP levels in elderly patients with severe AS.
Discussion
Our study indicates that plasma BNP levels were inﬂuenced by a
complex interaction of clinical and echocardiographic parameters
in patients with severe AS. In patients with severe AS, plasma BNP
levels were inﬂuenced by age and were higher in elderly patients
than in younger patients, despite the similar severity of AS in this
study. Furthermore, plasma BNP levels were inﬂuenced by other
variables in addition to AS severity in elderly patients, including
LV systolic and diastolic function, and anemia. In particular, elderly
patients have been shown to have decreased e′ and increased E/e′,
probably due to aged-related progression of LV diastolic dysfunc-
tion [9,10], and this may contribute to elevated plasma BNP levels
in elderly patients with AS. These additional associations need to
be considered in interpreting plasma BNP levels and deciding the
therapeutic strategy in patients with severe AS.
As previously reported [2,18–20], AS severity was signiﬁcantly
correlated with plasma BNP levels in this study. On the other hand,
AS severity did not emerge as an independent determinant of BNP
in elderly patients. E/e′ has been found to be a reliable estimate of
LV ﬁlling pressure, and was shown to be an independent predic-
tor of prognosis in patients with severe AS [21,22]. Since systolic
pressure overload leads to LV wall hypertrophy and decreased LV
compliance, LV end-diastolic pressure increases before LV dilation,
resulting in diastolic rather than systolic dysfunction in AS [23–26].
′In elderly patients, but not younger patients, E/A and e (parameters
of diastolic dysfunction) were correlated with plasma BNP levels
in univariate analysis. Age-related LV diastolic dysfunction might
play a more important role in the elevation of plasma BNP levels
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Table 4
Factors associated with log B-type natriuretic peptide in univariate and multivariate linear regression analyses.
Variable <75 years ≥75 years
Univariate Multivariate Univariate Multivariate
r p-Value ˇ p-Value r p-Value ˇ p-Value
Age 0.255 0.002 – – 0.330 <0.001 0.130 0.033
Atrial ﬁbrillation 0.214 0.012 0.170 0.018 0.199 0.005 0.150 0.011
Beta blocker use 0.220 0.009 0.204 0.004 0.149 0.036 0.126 0.026
Hemoglobin −0.065 0.442 – – −0.231 0.001 −0.180 0.002
Creatinine clearance −0.221 0.009 – – −0.089 0.210 – –
EDV index 0.255 0.002 – – 0.256 <0.001 – –
ESV index 0.349 <0.001 – – 0.396 <0.001 – –
Ejection fraction −0.328 <0.001 −0.180 0.015 −0.430 <0.001 −0.277 <0.001
LV mass index 0.483 <0.001 0.254 0.002 0.482 <0.001 0.270 <0.001
AVA index −0.360 <0.001 −0.253 0.001 −0.334 <0.001 – –
Peak AV velocity 0.310 <0.001 0.309 <0.001
Mean AV PG 0.331 <0.001 0.365 <0.001
E/A 0.168 0.054 – – 0.267 <0.001 – –
E/e′ 0.434 <0.001 0.200 0.010 0.401 <0.001 0.212 <0.001
e′ 0.101 0.248 – – 0.140 0.049 – –
0
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nﬂow; A, peak velocity of late diastolic ﬂow of mitral inﬂow; e′ , early diastolic ann
n elderly than younger patients with AS. Hemoglobin levels also
an decrease with age. Age and anemia were independently asso-
iated with plasma BNP level in our study, as previously reported
n a population without AS [11,27].
Several reports demonstrated a relationship between plasma
NP levels and the presence of symptoms [18–20]. However, symp-
oms did not emerge as an independent correlate of plasma BNP
evels in our series. This might be because we included chest pain
nd syncope as well as exertional dyspnea as symptoms in our
tudy, and chest pain and syncope have not been shown to be
ssociated with natriuretic peptide levels [18]. In addition, approx-
mately 30% of patients had coronary artery disease in our study,
hich could have caused their symptoms, especially chest pain.
Independent clinical correlates of plasma BNP levels were
trial ﬁbrillation and beta-blocker use in both groups. It has been
eported that plasma BNP levels increase in patients with atrial
brillation sinceBNP is produced in the atrium[28,29].On theother
and, since beta-blockersmay improve long-term systolic function
n patients with reduced ejection fraction or reduce afterload in
atients with hypertension, these changes might have inﬂuenced
lasma BNP levels [6,30]. In our echocardiographic evaluation, LV
jection fraction, LV mass index, and eSPAP were also indepen-
ent correlates of plasma BNP levels in both groups, as previously
eported [6,30,20,31,32]. On the other hand, creatinine clearance
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was not selected as an independent determinant of plasma BNP
levels in this study, although it had a signiﬁcant correlation with
plasmaBNP levels in the younger group.Namely, plasmaBNP levels
were more inﬂuenced by cardiac dysfunction than by renal dys-
function. This ﬁndingwas assumed to be consistentwith a previous
report that plasma BNP levels are a useful biomarker for mortality
and cardiovascular events in patients with chronic kidney disease
[33].
In regard to AS severity, AVA, peak AV velocity, and mean AV
pressure gradient have a close relationship and these cannot be
incorporated together into the logistic regression models for mul-
ticollinearity. We used AVA index to assess the AS severity in our
study, because it was reported that elderly patients with severe
AS often had low ﬂow and low-pressure gradient despite pre-
served ejection fraction [17]. In such patients, the assessment of
AS severity using pressure gradient or peak velocity could result in
underestimation of the AS severity and AVA index was assumed to
reﬂect the hemodynamic AS severity most among them.
LimitationsThere were some limitations of our study. Our data were ret-
rospectively derived from a modest number of patients. The role
of plasma BNP levels for risk stratiﬁcation and clinical decision
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aking in patients with severe AS could not be assessed in the
resent study. Plasma BNP level measurements were not serially
ollowed and the prognostic value of plasma BNP levels could not
e assessed. In addition, plasma BNP level has been reported to be
arkedly elevated in low-ﬂow, low-gradient AS and was signiﬁ-
antly higher in truly severe AS compared with pseudo-severe AS
4]. Since we evaluated the severity of AS only from AVA in this
tudy, we might have included patients with pseudo-severe AS.
linical implication
Currently, recognition of symptoms is critical to the selection of
therapeutic strategy, since the indication for surgery is largely
ased on the presence or absence of symptoms [34]. However,
ymptoms are often unclear particularly in elderly patients and
ight not reﬂect AS severity [35]. Furthermore, LV dysfunction
aused by AS could progress without evident symptoms and be
ssociated with poor outcome [34]. Plasma BNP level is a predictor
f outcome and helpful for risk stratiﬁcation of AS [2–4] reﬂect-
ng myocardial damage, and BNP might be useful in determining
he optimal timing of surgical interventions in such patients with
evere AS. In this study, AVA index was one of the strongest deter-
inants of plasmaBNP levels in youngerpatients.Namely, elevated
V wall stress and hypertrophy were mainly caused by AS and sur-
ical AVR might be effective in improving myocardial damage and
ysfunction in these patients. On the other hand, AVA index was
ot an independent determinant of elevated plasma BNP levels and
ther factors, rather than AS, were more associated with elevated
lasma BNP levels in elderly patients even with severe AS. Thus,
urgical AVR might not be effective in improving myocardial dam-
ge and dysfunction in elderly AS patients with elevated plasma
NP levels, and plasma BNP levels might not be useful to help
etermine the timing of surgical interventions in these patients.
therwise, our results can be interpreted in a different way. Age-
elated LV diastolic dysfunction might not be the sole reason why
lderly patients had decreased e′ and increased E/e′ compared with
ounger patients. Namely, elderly patients have a longer disease
eriod than younger patients, and could have more severe myocar-
ial damage due to longer LV pressure overload caused by AS. If so,
igher BNPmight indicate severemyocardial damage caused byAS,
rrespective of the current AVA index, and rather could be “useful
o help determine the timing of surgical interventions” in elderly
atients. However, we need further investigations to reach deﬁni-
ive conclusions. Anyway, we need to remember that plasma BNP
evels may be inﬂuenced more by factors other than AS severity in
lderly patients.
onclusion
Clinical and echocardiographic determinants of plasma BNP
evels were different between elderly and younger patients with
evere AS. Plasma BNP levels were higher in elderly patients than
n younger patients despite the similar severity of AS in this study.
urthermore, plasma BNP levels may be inﬂuenced more by other
actors such as LV diastolic dysfunction rather than by AS sever-
ty in elderly patients. We may need to take these factors into
onsideration in interpreting plasma BNP levels and deciding the
herapeutic strategy in severe AS.
undingThis work was partially supported by a Grant-in-Aid for Sci-
ntiﬁc Research C (24500554) from the Japan Society for the
romotion of Science (Masao Daimon).
[ology 64 (2014) 476–481
References
[1] Nkomo VT, Gardin JM, Skelton TN, Gottdiener JS, Scott CG, Enriquez-Sarano
M. Burden of valvular heart diseases: a population-based study. Lancet
2006;368:1005–11.
[2] Lim P, Monin JL, Monchi M, Garot J, Pasquet A, Hittinger L, Vanoverschelde
JL, Carayon A, Gueret P. Predictors of outcome in patients with severe aortic
stenosis andnormal left ventricular function: role of B-typenatriuretic peptide.
Eur Heart J 2004;25:2048–53.
[3] Monin JL, Lancellotti P, Monchi M, Lim P, Weiss E, Piérard L, Guéret P. Risk
score for predicting outcome in patients with asymptomatic aortic stenosis.
Circulation 2009;120:69–75.
[4] Bergler-Klein J, Mundigler G, Pibarot P, Burwash IG, Dumesnil JG, Blais C, Fuchs
C, Mohty D, Beanlands RS, Hachicha Z, Walter-Publig N, Rader F, Baumgart-
ner H. B-type natriuretic peptide in low-ﬂow, low-gradient aortic stenosis:
relationship to hemodynamics and clinical outcome: results from the Mul-
ticenter Truly or Pseudo-Severe Aortic Stenosis (TOPAS) study. Circulation
2007;115:2848–55.
[5] YamamotoK, Burnett Jr JC, JougasakiM,NishimuraRA, BaileyKR, Saito Y,Nakao
K, Redﬁeld MM. Superiority of brain natriuretic peptide as a hormonal marker
of ventricular systolic and diastolic dysfunction and ventricular hypertrophy.
Hypertension 1996;28:988–94.
[6] Yamamoto K, Burnett Jr JC, Bermudez EA, Jougasaki M, Bailey KR, Redﬁeld MM.
Clinical criteria and biochemical markers for the detection of systolic dysfunc-
tion. J Card Fail 2000;6:194–200.
[7] Lund O, Flø C, Jensen FT, Emmertsen K, Nielsen TT, Rasmussen BS, Hansen
OK, Pilegaard HK, Kristensen LH. Left ventricular systolic and diastolic func-
tion in aortic stenosis. Prognostic value after valve replacement and underlying
mechanisms. Eur Heart J 1997;18:1977–87.
[8] Grewal J, McKelvie R, Lonn E, Tait P, Carlsson J, Gianni M, Jarnert C, Persson H.
BNP and NT-proBNP predict echocardiographic severity of diastolic dysfunc-
tion. Eur J Heart Fail 2008;10:252–9.
[9] Villari B, Vassalli G, Schneider J, Chiariello M, Hess OM. Age dependency of
left ventricular diastolic function in pressure overload hypertrophy. J Am Coll
Cardiol 1997;29:181–6.
10] Daimon M, Watanabe H, Abe Y, Hirata K, Hozumi T, Ishii K, Ito H, Iwakura
K, Izumi C, Matsuzaki M, Minagoe S, Abe H, Murata K, Nakatani S, Negishi K,
et al. Gender differences in age-related changes in left and right ventricular
geometries and functions. Echocardiography of a healthy subject group. Circ J
2011;75:2840–6.
11] Redﬁeld MM, Rodeheffer RJ, Jacobsen SJ, Mahoney DW, Bailey KR, Burnett Jr
JC. Plasma brain natriuretic peptide concentration: impact of age and gender. J
Am Coll Cardiol 2002;40:976–82.
12] Otto CM, Pearlman AS, Comess KA, Reamer RP, Janko CL, Huntsman LL.
Determination of the stenotic aortic valve area in adults usingDoppler echocar-
diography. J Am Coll Cardiol 1986;7:509–17.
13] Lang RM, Bierig M, Devereux RB, Flachskampf FA, Foster E, Pellikka PA, Picard
MH, Roman MJ, Seward J, Shanewise JS, Solomon SD, Spencer KT, Sutton MS,
Stewart WJ, Chamber Quantiﬁcation Writing Group, et al. Recommendations
for chamber quantiﬁcation: a report from theAmerican Society of Echocardiog-
raphy’s Guidelines and Standards Committee and the Chamber Quantiﬁcation
Writing Group, developed in conjunction with the European Association of
Echocardiography, a branch of the European Society of Cardiology. J Am Soc
Echocardiogr 2005;18:1440–63.
14] Nagueh SF, Appleton CP, Gillebert TC, Marino PN, Oh JK, Smiseth OA, Wag-
goner AD, Flachskampf FA, Pellikka PA, Evangelista A. Recommendations for
the evaluation of left ventricular diastolic function by echocardiography. J Am
Soc Echocardiogr 2009;22:107–33.
15] Rudski LG, Lai WW, Aﬁlalo J, Hua L, Handschumacher MD, Chandrasekaran
K, Solomon SD, Louie EK, Schiller NB. Guidelines for the echocardiographic
assessment of the right heart in adults: a report from the American Society of
Echocardiography endorsed by the European Association of Echocardiography,
a registered branch of the European Society of Cardiology, and the Canadian
Society of Echocardiography. J Am Soc Echocardiogr 2010;23:685–713.
16] Canepa M, Strait JB, Abramov D, Milaneschi Y, AlGhatrif M, Moni M. Con-
tribution of central adiposity to left ventricular diastolic function (from
the Baltimore Longitudinal Study of Aging). Am J Cardiol 2012;109:
1171–8.
17] Hachicha Z, Dumesnil JG, Bogaty P, Pibarot P. Paradoxical low-ﬂow, low-
gradient severe aortic stenosis despite preserved ejection fraction is associated
with higher afterload and reduced survival. Circulation 2007;115:2856–64.
18] Gerber IL, Stewart RA, Legget ME, West TM, French RL, Sutton TM, Yandle TG,
French JK, Richards AM, White HD. Increased plasma natriuretic peptide levels
reﬂect symptom onset in aortic stenosis. Circulation 2003;107:1884–90.
19] Bergler-Klein J, Klaar U, Heger M, Rosenhek R, Mundigler G, Gabriel H, Binder
T, Pacher R, Maurer G, Baumgartner H. Natriuretic peptides predict symptom-
free survival and postoperative outcome in severe aortic stenosis. Circulation
2004;109:2302–8.
20] MaréchauxS,HattabiM, Juthier F,NeicuDV,RichardsonM,Carpentier E, Bouab-
dallaoui N, Delelis F, Banﬁ C, Breyne J, Jude B, Asseman P, Vincentelli A, Le
Tourneau T, Graux P, et al. Clinical and echocardiographic correlates of plasma
B-type natriuretic peptide levels in patients with aortic valve stenosis and
normal left ventricular ejection fraction. Echocardiography 2011;28:695–702.
21] Biner S, Raﬁque AM, Goykhman P, Morrissey RP, Naghi J, Siegel RJ. Progno-
stic value of E/E′ ratio in patients with unoperated severe aortic stenosis. JACC
Cardiovasc Imaging 2010;3:899–907.
Cardi
[
[
[
[
[
[
[
[
[
[
[
[
[
agement of patients with valvular heart disease). J Am Coll Cardiol 2006;48:S. Sasaki et al. / Journal of
22] Bruch C, Stypmann J, Grude M, Gradaus R, Breithardt G, Wichter T. Tissue
Doppler imaging in patients with moderate to severe aortic valve stenosis:
clinical usefulness and diagnostic accuracy. Am Heart J 2004;148:696–702.
23] Hess OM, Ritter M, Schneider J, Grimm J, Turina M, Krayenbuehl HP. Diastolic
stiffness and myocardial structure in aortic valve disease before and after valve
replacement. Circulation 1984;69:855–65.
24] Murakami T, Hess OM, Gage JE, Grimm J, Krayenbuehl HP. Diastolic ﬁlling
dynamics in patients with aortic stenosis. Circulation 1986;73:1162–74.
25] Hess OM, Villari B, Krayenbuehl HP. Diastolic dysfunction in aortic stenosis.
Circulation 1993;87:73–6.
26] Gaasch WH. Diagnosis and treatment of heart failure based on left ventricular
systolic or diastolic dysfunction. J Am Med Assoc 1994;271:1276–80.
27] Hogenhuis J, Voors AA, Jaarsma T, Hoes AW, Hillege HL, Kragten JA, van Veld-
huisen DJ. Anaemia and renal dysfunction are independently associated with
BNP and NT-proBNP levels in patients with heart failure. Eur J Heart Fail
2007;9:787–94.
28] Silvet H, Young-Xu Y, Walleigh D, Ravid S. Brain natriuretic peptide is elevated
in outpatients with atrial ﬁbrillation. Am J Cardiol 2003;92:1124–7.
29] Inoue S, Murakami Y, Sano K, Katoh H, Shimada T. Atrium as a source of
brain natriuretic polypeptide in patients with atrial ﬁbrillation. J Card Fail
2000;6:92–6.
30] McDonagh TA, Robb SD, Murdoch DR, Morton JJ, Ford I, Morrison CE, Tunstall-
Pedoe H, McMurray JJ, Dargie HJ. Biochemical detection of left-ventricular
dysfunction. Lancet 1998;351:9–13.
[ology 64 (2014) 476–481 481
31] Orlowska-Baranowska E, Baranowski R, Greszata L, Stepinska J. Brain natri-
uretic peptide as amarker of left ventricular hypertrophy inpatientswith aortic
stenosis. J Heart Valve Dis 2008;17:598–605.
32] Leuchte HH, Holzapfel M, Baumgartner RA, Ding I, Neurohr C, Vogeser M,
Kolbe T, Schwaiblmair M, Behr J. Clinical signiﬁcance of brain natriuretic
peptide in primary pulmonary hypertension. J Am Coll Cardiol 2004;43:
764–70.
33] Horii M, Matsumoto T, Uemura S, Sugawara Y, Takitsume A, Ueda T, Nakagawa
H, Nishida T, Soeda T, Okayama S, Somekawa S, Ishigami K, Takeda Y, Kawata H,
Kawakami, et al. Prognostic value of B-type natriuretic peptide and its amino-
terminal proBNP fragment for cardiovascular eventswith stratiﬁcationby renal
function. J Cardiol 2013;61:410–6.
34] Bonow RO, Carabello BA, Chatterjee K, de Leon Jr AC, Faxon DP, Freed
MD, Gaasch WH, Lytle BW, Nishimura RA, O’Gara PT, O’Rourke RA, Otto
CM, Shah PM, Shanewise JS. ACC/AHA 2006 guidelines for the manage-
ment of patients with valvular heart disease: a report of the American
College of Cardiology/American Heart Association Task Force on Practice
Guidelines (Writing Committee to revise the 1998 guidelines for the man-e1–148.
35] Nishizaki Y, Daimon M, Miyazaki S, Suzuki H, Kawata T, Miyauchi K, Chiang
SJ, Makinae H, Shinozaki T, Daida H. Clinical factors associated with classical
symptoms of aortic valve stenosis. J Heart Valve Dis 2013;22:287–94.
